Edesa Biotech (EDSA) Prepaid Assets (2013 - 2026)
Edesa Biotech (EDSA) posted Prepaid Assets of $234414.0 for Q4 2025, up 201.16% sequentially from $77838.0 in Q3 2025, and up 48.56% YoY from $157787.0 in Q4 2024.
Edesa Biotech (EDSA) Prepaid Assets (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Prepaid Assets for 13 years, with the latest figure at $234414.0 in Q4 2025.
- Quarterly Prepaid Assets rose 48.56% year-over-year to $234414.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $234414.0 (up 48.56% YoY) and the FY2025 annual result came in at $77838.0, down 78.81% from the prior year.
- Prepaid Assets climbed to $234414.0 in Q4 2025 per EDSA's latest filing, from $77838.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $2.6 million in Q1 2021 and troughed at $77838.0 in Q3 2025.
- A 5-year average of $690454.9 and a median of $451799.0 in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2021 and 2025: Prepaid Assets soared 650.57% in 2021, then slumped 78.81% in 2025.
- Over 5 years, Prepaid Assets stood at $1.1 million in 2021, then tumbled by 39.11% to $690945.0 in 2022, then sank by 41.4% to $404903.0 in 2023, then tumbled by 61.03% to $157787.0 in 2024, then soared by 48.56% to $234414.0 in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $234414.0, $77838.0, and $112659.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 219,707.00 |
| Dec 31, 2025 | 234,414.00 |
| Sep 30, 2025 | 77,838.00 |
| Jun 30, 2025 | 112,659.00 |
| Mar 31, 2025 | 108,199.00 |
| Dec 31, 2024 | 157,787.00 |
| Sep 30, 2024 | 367,394.00 |
| Jun 30, 2024 | 454,686.00 |
| Mar 31, 2024 | 330,267.00 |
| Dec 31, 2023 | 404,903.00 |
| Sep 30, 2023 | 448,912.00 |
| Jun 30, 2023 | 414,045.00 |
| Mar 31, 2023 | 608,109.00 |
| Dec 31, 2022 | 690,945.00 |
| Sep 30, 2022 | 745,543.00 |
| Jun 30, 2022 | 968,061.00 |
| Mar 31, 2022 | 863,319.00 |
| Dec 31, 2021 | 1.13 Mn |
| Sep 30, 2021 | 948,645.00 |
| Jun 30, 2021 | 2.10 Mn |